Patient Guide: Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 6 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06649006
Status: ACTIVE_NOT_RECRUITING
Condition: B-precursor Acute Lymphoblastic Leukemia
Phase: PHASE1

Where You Can Participate

This study is available at 6 locations across the country.

Top locations include:
  • • Akita-shi, Akita
  • • Fukuoka-shi, Fukuoka
  • • Kurume-shi, Fukuoka
  • • And 3 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) - Join Clinical Trial NCTNCT06649006

How to Join This Clinical Trial - NCTNCT06649006

Learn how to participate in this PHASE1 trial studying an investigational therapy for B-precursor Acute Lymphoblastic Leukemia. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with B-precursor Acute Lymphoblastic Leukemia. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
B-precursor Acute Lymphoblastic Leukemia
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT06649006 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 6 locations. Find a study site near you:

Clinical Research Site

Akita-shi, Akita 010-8543 - Japan

Status: Contact for availability

Clinical Research Site

Fukuoka-shi, Fukuoka 812-8582 - Japan

Status: Contact for availability

Clinical Research Site

Kurume-shi, Fukuoka 830-0011 - Japan

Status: Contact for availability

Clinical Research Site

Fukushima-shi, Fukushima 960-1295 - Japan

Status: Contact for availability

Clinical Research Site

Kanazawa-shi, Ishikawa 920-8641 - Japan

Status: Contact for availability

Clinical Research Site

Yamagata-shi, Yamagata 990-9585 - Japan

Status: Contact for availability

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for B-precursor Acute Lymphoblastic Leukemia:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships